Now showing items 1-10 of 18
Radiation therapy combined with hormone treatment for primary prostate cancer. Effects of radiation dose escalations and assessment of side effects
(The University of Bergen, 2009-05-06)
Adjuvant treatment: the contribution of expression microarrays
(BioMed Central, 2007-12-20)
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
(BioMed Central, 2010-06-21)
Background The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and ...
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
(Public Library of Science, 2008-08-26)
Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis ...
MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
(Public Library of Science, 2012-04-30)
The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been ...
Genetic biomarkers as prognostic and predictive factors in metastatic malignant melanoma
(The University of Bergen, 2010-10-26)
Malignant melanoma is one of the most chemoresistant malignancies in man. Although effort is put into developing new drugs to treat metastatic melanoma, still dacarbazine, an alkylating agent approved in 1975 for therapeutic ...
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
(Public Library of Science, 2011-04-27)
Background: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may ...
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
(BioMed Central, 2012-08-14)
<p>Introduction: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to ...
Inflammatory biomarkers with focus on Calprotectin (S100A8/S100A9) and S100A12 (EN-RAGE) : method development and application in acute radiation proctitis and rheumatoid arthritis patients
(The University of Bergen, 2007-02-02)
Assessments of diseases are usually performed by a combination of clinical symptoms, signs and objective measurements. Biochemical markers of inflammation are important in evaluation of treatment of acute and chronic ...
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
(BioMed Central, 2010-03-25)
Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to ...